Registry of Acute Myocardial Infarction
Launched by TOMSK NATIONAL RESEARCH MEDICAL CENTER OF THE RUSSIAN ACADEMY OF SCIENCES · Feb 1, 2024
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
The Registry of Acute Myocardial Infarction (RAMI) is a clinical trial designed to collect and analyze information about cases of acute myocardial infarction (AMI), which is commonly known as a heart attack. The goal of this study is to improve the way doctors diagnose and track heart attack cases by gathering data from all healthcare facilities in the city of Tomsk. If you are at least 20 years old and have experienced a heart attack, or have had symptoms that suggest a heart attack while visiting or living in Tomsk, you might be eligible to participate.
Participants in this trial will help researchers better understand heart attacks by providing important information about their symptoms and medical history. There are no specific exclusion criteria, meaning almost anyone who meets the age and residency requirements can join. By participating, individuals will contribute to a valuable resource that could lead to improved heart attack diagnosis and treatment in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age of at least 20 years;
- • being a resident or visitor of the city of Tomsk at a time of AMI onset;
- • the presence of definite AMI or possible AMI. Definite AMI is diagnosed in the presence of characteristic ECG changes, regardless of clinical course and changes in serum enzymes; or the presence of typical pain syndrome, "ambiguous" ECG changes, and definite increase in the activity of serum enzymes i.e. exceeding the upper limit of normal by 25% or more; or macroscopically detected focus of myocardial necrosis and (or) fresh thrombotic occlusion of the coronary artery. Possible AMI is registered in the presence of typical pain syndrome with ambiguous ECG changes and an ambiguous (up to 25%) increase in the levels of serum enzymes; or the presence of obstruction in the lumen of at least one coronary artery by at least 50% and (or) the presence of a post-infarction scar in the myocardium with a diameter of 0.5 cm or more, while simultaneously excluding a non-coronary cause of death. In case of atypical clinical picture, ambiguous or absent ECG changes, when the enzyme levels are not determined or their activity does not reach a pathological level, AMI case is considered unconfirmed. In the absence of data that could confirm or not confirm AMI, the case is interpreted as "insufficient data"
- Exclusion Criteria:
- • none.
About Tomsk National Research Medical Center Of The Russian Academy Of Sciences
The Tomsk National Research Medical Center of the Russian Academy of Sciences is a leading clinical research institution dedicated to advancing medical science and healthcare innovation. Committed to high standards of clinical excellence, the center integrates cutting-edge research with patient care, focusing on a diverse range of medical disciplines. With a robust infrastructure and a multidisciplinary team of experts, the center actively sponsors and conducts clinical trials aimed at improving diagnostic, therapeutic, and preventive strategies, ultimately contributing to the global body of medical knowledge and enhancing patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tomsk, , Russian Federation
Patients applied
Trial Officials
Alexei N. Repin, MD, PhD
Study Director
Tomsk NRMC
Sergey A. Okrugin, MD, PhD
Principal Investigator
Tomsk NRMC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported